# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-22-006304
Filing Date
2022-04-28
Accepted
2022-04-28 16:25:28
Documents
5
Period of Report
2022-06-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tmb-20220616xdef14a.htm | DEF 14A | 908013
2 | GRAPHIC | tmb-20220616xdef14a020.jpg | GRAPHIC | 173597
3 | GRAPHIC | tmb-20220616xdef14a018.jpg | GRAPHIC | 127706
4 | GRAPHIC | tmb-20220616xdef14a017.jpg | GRAPHIC | 185419
5 | GRAPHIC | tmb-20220616xdef14a019.jpg | GRAPHIC | 276775
| Complete submission text file | 0001558370-22-006304.txt |  | 1960996

Mailing Address 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107
Business Address 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39712 | Film No.: 22867056
SIC: 2834 Pharmaceutical Preparations